Details

Autor(en) / Beteiligte

• Shao, M
• Guo, H F
• Lei, L Y
• Zhao, Q
• Ding, Y J
• Lin, J
• Wu, R
• Yu, F
• Li, Y C
• Miao, H L
• Zhang, L Y
• DU, Y
• Jiao, R Y
• Pang, L X
• Long, L
• Li, Z G
• Li, R

Titel

A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus

Ist Teil von

• Beijing da xue xue bao. Journal of Peking University. Yi xue ban, 2022-12, Vol.54 (6), p.1112-1116

Ort / Verlag

China

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• To compare the safety of low-dose cyclophosphamide and high-dose cyclophosphamide in the treatment of systemic lupus erythematosus (SLE). A total of 1 022 patients with systemic lupus erythematosus from 24 hospitals in China between March 2017 to July 2018 were enrolled. Their clinical manifestations, laboratory tests, adverse events, reasons for stopping receiving intravenous cyclophosphamide and comorbidities were collected. Among them, 506 SLE patients received short-interval low-dose intravenous cyclophosphamide therapy (SILD IV-CYC, 400 mg every two weeks), and 256 patients underwent high-dose cyclophosphamide therapy (HD IV-CYC, 500 mg/m of body surface area every month), the side effects between the two groups were compared, the remaining 260 SLE patients were treated with IV-CYC irregularly. Moreover, a total of 377 patients in SILD IV-CYC group and 214 patients in HD IV-CYC group had medical records of the reasons for stopping recei-ving IV-CYC. The reasons for stopping receiving IV-CYC in these two